Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge assists SJ with financing from NIB
Mandate

Vinge assists SJ with financing from NIB

April 22, 2009

Vinge has advised SJ AB in connection with a financing transaction in which SJ is borrowing approximately SEK 500,000,000 (MEUR 45) from the Nordic Investment Bank (NIB) in order to partly finance 20 new high-speed trains. The new trains will constitute the base for SJ’s new traffic system and will be delivered during 2010.

”NIB imposes stringent demands for granting loan facilities and SJ had a significant advantage as a result of the positive environmental aspects which flow from development of, and investment in, train services in Sweden” says Fredrik Wilkens, partner at Vinge.

Vinge’s team consisted of responsible partner Fredrik Wilkens and associates Emma Stuart-Beck and Katarina Rykowska.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024